Miroslaw Mazurczak
Expertise in
77
conditions

Dr. Miroslaw Mazurczak

Oncology | Hematology
1309 W. 17th St., 
Sioux Falls, SD 
Offers Telehealth
Expertise in
77
conditions
1309 W. 17th St., 
Sioux Falls, SD 

Overview

Miroslaw Mazurczak is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota.

Dr. Mazurczak is highly rated in 77 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Pancreatic Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Dr. Mazurczak is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Oncology. He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 8 clinical trials.

Residency

Easton Hospital, Internal Medicine

Specialties

Oncology
Hematology

Licenses

Internal Medicine in SD

Board Certifications

American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Oncology

Fellowships

State University of New York, Hematology & Oncology

Hospital Affiliations

Sanford Worthington Medical Center
Sanford Vermillion Medical Center
Sanford Sheldon Medical Center
Sanford Canby Medical Center
Sanford Usd Medical Center

Languages Spoken

English
Polish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

Sanford Cancer Center
1309 W. 17th St., Sioux Falls, SD 57104
Other Locations
Sanford Worthington Cancer Center
1018 Sixth Ave., Worthington, MN 56187
Sanford Clear Lake Medical Center
701 Third Ave. S., Clear Lake, SD 57226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: May 05, 2026
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

11 Total Publications

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.
Journal: Neuro-oncology
Published: June 28, 2025
Similar Doctors
Expertise in
53
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Expertise in
53
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Referral may be required

Avera Medical Group Hematology

1000 E 23rd St Ste 200, 
Sioux Falls, SD 
 (1.2 miles away)
605-322-3035
Languages Spoken:
English
See accepted insurances

Vinod Parameswaran is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota. Dr. Parameswaran is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Diencephalic Syndrome, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
51
conditions
Dr. Christopher Sumey
Oncology | Hematology
Expertise in
51
conditions
Dr. Christopher Sumey
Oncology | Hematology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (0.1 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Christopher Sumey practices hematology and oncology in Sioux Falls, South Dakota.He treats all subtypes of cancer and hematologic conditions. Dr. Sumey is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sumey is board certified in American Board Of Internal MedicineAmerican Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: Hematology.

Expertise in
38
conditions
Dr. Steven Powell
Hematology | Oncology
Expertise in
38
conditions
Dr. Steven Powell
Hematology | Oncology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (0.1 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Steven Powell is an oncology and hematology physician who specializes in treating lung, head and neck cancer and melanoma. Dr. Powell is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Olfactory Neuroblastoma, Pleuropulmonary Blastoma, Melanoma, and Bone Marrow Aspiration. Dr. Powell is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: Internal Medicine.

Frequently Asked Questions about Dr. Miroslaw Mazurczak

How do I make an appointment with Dr. Miroslaw Mazurczak?

You can book an appointment with Dr. Miroslaw Mazurczak by calling their office at 605-328-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Miroslaw Mazurczak a top-rated expert for Large-Cell Immunoblastic Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Miroslaw Mazurczak is classified as an Distinguished expert for Large-Cell Immunoblastic Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Miroslaw Mazurczak specialize in?

While Dr. Miroslaw Mazurczak is a Oncology, they have specific expertise in Large-Cell Immunoblastic Lymphoma, Pancreatic Cancer, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Miroslaw Mazurczak participate in research or clinical trials?

Yes. Dr. Miroslaw Mazurczak has published 11 articles and abstracts on conditions like Large-Cell Immunoblastic Lymphoma. You can view a list of Dr. Miroslaw Mazurczak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Miroslaw Mazurczak accept my insurance?

Dr. Miroslaw Mazurczak accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 605-328-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mazurczak's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 63 Advanced Conditions
    View All 147 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile